Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

859.90INR
1 Apr 2015
Change (% chg)

-- (--)
Prev Close
Rs859.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
0
52-wk High
Rs869.00
52-wk Low
Rs551.00

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.44
Market Cap(Mil.): Rs365,985.50
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): -- 37.25 40.68
EPS (TTM): -19.13 -- --
ROI: -- 16.52 15.78
ROE: -- 17.30 16.82
Search Stocks

Sun Pharma slumps 16 percent, heads towards biggest ever fall on sales warning

MUMBAI - Sun Pharmaceutical Industries shares slumped 16 percent on Tuesday, heading towards their biggest ever fall in a day, after the drugmaker's warning that 2016 sales would be flat at best due to costs related to remediation work at its plants.

21 Jul 2015

REFILE-UPDATE 1-India's Sun Pharma heads towards biggest ever fall on sales warning

* Sun Pharma expects "sustainable growth trajectory" after 2016

21 Jul 2015

India's Sun Pharma slumps, heads towards biggest fall ever

MUMBAI, July 21 - Shares in India's Sun Pharmaceutical Industries slumped 16 percent, heading towards their biggest daily fall ever, after the drugmaker on Monday said it sees 2016 sales flat at best.

21 Jul 2015

BUZZ-India's Sun Pharma's flat sales guidance may dent premium valuations

** Sun Pharmaceutical Industries may fall sharply, denting its premium valuations for near term

21 Jul 2015

Sun Pharma sees 2016 sales flat at best, may shed assets

MUMBAI - India's largest drugmaker, Sun Pharmaceutical Industries Ltd , said on Monday its revenue in fiscal 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.

20 Jul 2015

UPDATE 1-India's Sun Pharma sees 2016 sales flat at best, may shed assets

* Says remedial action at Ranbaxy's plants "on track" (Adds managing director's comments from conference call)

20 Jul 2015

India's Sun Pharma expects Ranbaxy costs to hit 2016 revenue

MUMBAI, July 20 - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Monday its fiscal 2016 revenue might decline or stay flat due to costs related to fixing manufacturing issues at Ranbaxy Laboratories, which it bought for $3.2 billion last year.

20 Jul 2015

BUZZ-India's Sun Pharma rises; Credit Suisse says Ranbaxy drug prices hiked

** Company hikes prices in unit Ranbaxy Laboratories' US-branded portfolio - Credit Suisse

30 Jun 2015

BUZZ-India's Sun Pharma slumps as much as 10 pct on Q4 results

** Sun Pharmaceutical Industries slumps as much as 10 pct to 869.10 rupees as of 0445 GMT, its lowest since Feb. 27

01 Jun 2015

Sun Pharma misses profit estimates on Ranbaxy costs

MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.

29 May 2015

Earnings vs. Estimates

Search Stocks